GC
OVID icon

Globeflex Capital’s Ovid Therapeutics OVID Stock Holding History

Globeflex Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,305,588
Closed -$4.1M – 507
2022
Q1 		$4.1M Sell
1,305,588
-91,829
-7% -$289K 0.83% 19
2021
Q4 		$4.49M Sell
1,397,417
-353
-0% -$1.21K 0.92% 13
2021
Q3 		$4.7M Buy
1,397,770
+388,645
+39% +$1.42M 1.03% 12
2021
Q2 		$3.95M Buy
+1,009,125
New +$3.98M 0.71% 17

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Globeflex Capital's OVID Position: Q2 2022 in Review

Globeflex Capital sold out of Ovid Therapeutics (OVID) in Q2 2022, closing a stake of 1,305,588 shares — an estimated $4.1M sold.

Globeflex Capital first reported a position in OVID in Q2 2021 and held it in 4 quarters. The position peaked at $4.7M in Q3 2021. 55 funds tracked by Wall St. Rank hold OVID as of Q2 2022.

  • Globeflex Capital reported no remaining Ovid Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Globeflex Capital sold 1,305,588 Ovid Therapeutics shares in Q2 2022, an estimated $4.1M.
  • Globeflex Capital first reported a position in Ovid Therapeutics in Q2 2021 and held it in 4 quarters.
  • Globeflex Capital's Ovid Therapeutics position peaked at $4.7M in Q3 2021.
  • 55 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2022.

Based on Globeflex Capital's 13F filing for Q2 2022, filed 15 Aug 2022.